$1250 | Single User
$1800 | Site License
$2500 | Global License

Abdominal Obesity Metabolic Syndrome Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 20 Aug 2019 | 270547 | In Stock
Related Topics: Drug , Obesity

Introduction

Epidemiological Studies:

Our Senior Analysts for conducting Epidemiological Studies uses expertise and proprietary tools to understand the prevailing factors affecting the Disease population. Based on demographics, prevalent factors, incidence rate trends and many other geographical factors, Senior Analysts predicts the future numbers of the affected population over the forecast period, even suggesting the preventative measures.

Deals Analytics:

The report bestows explicit information about the collaborations and partnering activities and trend in Abdominal Obesity Metabolic Syndrome landscape, including details about different deals types like Mergers and Acquisitions, Licensing deals, Partnering deals, Collaboration Agreements, Series Financings, Grants and Fundings, etc occurring between 2010-2020.

Patent Analytics of Pipeline Drugs:

The section even contains a thorough analysis on the intellectual property pertaining to Abdominal Obesity Metabolic Syndrome pipeline drugs. Profound analytics have been provided related to the patent issuance and applications, patent expiries, patent extensions, etc to gain a complete knowledge on the new market entries filling up the gaps due to the patent expiries.

Pipeline Drug Descriptions and Development Milestones:

Report provides detailed pipeline drugs descriptions covering all key aspects of the pipeline drugs like intended indications, mechanism of action, route of administration and role in pathophysiological conditions. Report even covers all development milestones of the pipeline drugs right from the early research and development to current stage of development.

Clinical Trial Analytics:

The report is inclusive of all the updated clinical trials information, providing details related to the completed clinical trials, ongoing clinical trials, planned clinical trials, even including complete analytics based on sponsors (companies, universities and institutes) involved in the development of Abdominal Obesity Metabolic Syndrome Therapeutics.

Competitive Landscape and Opportunity Assessments:

The report is an absolute package covering all the companies - Established and emerging companies (Clinical-stage companies, pre-clinical stage companies, startups) actively involved in the R&D of new therapeutics for the treatment of Abdominal Obesity Metabolic Syndrome. Report provided opportunity assessments by performing a competitive and comparative analysis on the top 20 Emerging companies in the competitive space.

Emerging Company Profiles:

Report features company profiles with data concentrated on: Partnering activities and patent analysis of the company, R&D efforts and advancements, Comparison of internal investment and external funding, Achievements of special regulatory allowances and Outline of in-licensing/out licensing opportunities.

Table of Contents
for Abdominal Obesity Metabolic Syndrome Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

  • CHAPTER 01: INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. METHODOLOGY

    1.3. ABOUT US: GERVANORA DATA SERVICES

    CHAPTER 02: EXECUTIVE SUMMARY

    2.1. REPORT SUMMARY

    2.2. KEY EVENTS IN THE ABDOMINAL OBESITY METABOLIC SYNDROME COMPETITIVE SPACE

    2.3. REPORT MAJOR FINDINGS

    2.3.1. DRIVERS

    2.3.2. RESTRAINTS

    2.3.3. OPPORTUNITIES

    CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

    3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS

    3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT

    3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY

    3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION

    3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS

    3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MECHANISM OF ACTION

    3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE

    3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET

    3.1.8. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE

    3.2. UNMET NEEDS AND MARKET DEMANDS

    3.2.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES

    3.2.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION

    3.2.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

    3.3 MARKET DYNAMICS OF ABDOMINAL OBESITY METABOLIC SYNDROME COMPETITIVE LANDSCAPE

    CHAPTER 04: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

    4.1. DISEASE DEFINITION AND SYMPTOMS

    4.2. DISEASE CAUSE AND PATHOPHYSIOLOGY

    4.3. DISEASE DIAGNOSIS

    4.4. TREATMENT ALGORITHM AND GUIDELINES

    4.5. EPIDEMIOLOGY STUDIES

    3.5.1. GLOBAL AND HISTORICAL TRENDS

    4.6. EPIDEMIOLOGY FORECAST

    4.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS

    4.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

    CHAPTER 05: DEALS (M&A) ANALYTICS OF ABDOMINAL OBESITY METABOLIC SYNDROME COMPETITIVE LANDSCAPE

    4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)

    4.1.1 DEALS ANALYTICS BY DEAL TYPE

    4.1.1.1. COLLABORATION DEALS

    4.1.1.2. LICENSING DEALS

    4.1.1.3. FINANCING DEALS

    4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY

    4.1.3 DEALS ANALYTICS BY ACTIVE PLAYER

    CHAPTER 06: PATENT ANALYTICS OF ABDOMINAL OBESITY METABOLIC SYNDROME PIPELINE DRUGS

    6.1. PATENT ANALYTICS BY GEOGRAPY

    6.2. PATENT ANALYTICS BY PATENT EXPIRY

    6.3. PATET ANALYTICS BY SPECIAL ALLOWANCES AND TERM EXTENSIONS

    CHAPTER 07: PIPELINE DRUGS ANALYTICS OF ABDOMINAL OBESITY METABOLIC SYNDROME

    7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT

    5.1.1. PRE-REGISTRATION PIPELINE DRUGS

    5.1.2. PHASE III PIPELINE DRUGS

    5.1.3. PHASE II PIPELINE DRUGS

    5.1.4. PHASE I/II PIPELINE DRUGS

    5.1.5. PHASE I PIPELINE DRUGS

    5.1.6. PRE-CLINICAL PIPELINE DRUGS

    5.1.7. EARLY R&D PIPELINE DRUGS

    5.1.8. INACTIVE AND DISCONTINOUED PIPELINE DRUGS

    5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY

    5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION

    5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS

    5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION

    5.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE

    5.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS

    5.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

    CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.4. PHASE I/II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.5. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    CHAPTER 09: ESTIMATED APPROVAL TIMELINES OF ABDOMINAL OBESITY METABOLIC SYNDROME PIPELINE DRUGS

    7.1. METHODOLOGY

    7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

    CHAPTER 10: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

    8.1. EXTERNAL DEPENDENCIES

    8.1.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING

    8.2. PIPELINE PORTFOLIO

    8.3. EXPECTED MARKET ENTRIES

    8.4. PATENTS AND EXCLUSIVITY

    8.5. MARKET DYNAMICS AND PARTNERING

    8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES

    8.7. COMPANY DEVELOPMENTS

    CHAPTER 11: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    9.1. EMERGING COMPANIES

    9.1.1 EMERGING COMPANY PROFILES

List Of Tables
in Abdominal Obesity Metabolic Syndrome Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

LIST OF TABLES

• TABLE 01: ABDOMINAL OBESITY METABOLIC SYNDROME REPORT HIGHLIGHTS IN NUMERICALS

• TABLE 02: COLLABORATION DEALS IN ABDOMINAL OBESITY METABOLIC SYNDROME THERAPEUTIC AREA

• TABLE 03: LICENSING DEALS IN ABDOMINAL OBESITY METABOLIC SYNDROME THERAPEUTIC AREA

• TABLE 04: FINANCING DEALS IN ABDOMINAL OBESITY METABOLIC SYNDROME THERAPEUTIC AREA

• TABLE 5: ABDOMINAL OBESITY METABOLIC SYNDROME PHASE III PIPELINE MOLECULES

• TABLE 6: ABDOMINAL OBESITY METABOLIC SYNDROME PHASE II PIPELINE MOLECULES

• TABLE 7: ABDOMINAL OBESITY METABOLIC SYNDROME PHASE I/II PIPELINE MOLECULES

• TABLE 8: ABDOMINAL OBESITY METABOLIC SYNDROME PHASE I PIPELINE MOLECULES

• TABLE 9: PRECLINICAL STAGE DRUG CANDIDATES FOR ABDOMINAL OBESITY METABOLIC SYNDROME

• TABLE 10: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION

• TABLE 11: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION

• (Remaining Tables can be seen in detailed Report)

List Of Figures, Charts and Diagrams
in Abdominal Obesity Metabolic Syndrome Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

LIST OF FIGURES

• FIGURE 01: KEY EVENTS IN THE ABDOMINAL OBESITY METABOLIC SYNDROME COMPETITIVE SPACE

• FIGURE 02: ABDOMINAL OBESITY METABOLIC SYNDROME DEAL ANALYTICS BY DEAL TYPE

• FIGURE 03: ABDOMINAL OBESITY METABOLIC SYNDROME DEAL ANALYTICS BY DEAL FREQUENCY

• FIGURE 04: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D

• FIGURE 05: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT

• FIGURE 06: ABDOMINAL OBESITY METABOLIC SYNDROME DRUGS PIPELINE ANALYTICS BY ROA

• FIGURE 07: ABDOMINAL OBESITY METABOLIC SYNDROME DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA

• FIGURE 08: PARENTERAL DRUGS PIPELINE ANALYTICS BY HSD

• FIGURE 09: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT

• FIGURE 10: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES

• FIGURE 11: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT

• FIGURE 12: ABDOMINAL OBESITY METABOLIC SYNDROME PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES

• FIGURE 13: ABDOMINAL OBESITY METABOLIC SYNDROME PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE VS STAGE OF DEVELOPMENT

• FIGURE 14: ABDOMINAL OBESITY METABOLIC SYNDROME COMPANIES (NUMBER, PERCENT SHARE)

• FIGURE 15: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON ABDOMINAL OBESITY METABOLIC SYNDROME

• (Remaining Figures can be seen in detailed Report)

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270547 | GERPH177

Number of Pages

125

Report Format

PDF

Gervano R A Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Abdominal Pain Global Clinical Trials Review, H2, 2018
Abdominal Pain Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, “Ab...
25 Oct 2018 by Global Data USD $2,500 More Info
Abdominal Obesity Global Clinical Trials Review, H2, 2018
Abdominal Obesity Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, ...
25 Oct 2018 by Global Data USD $2,500 More Info
Abdominal Aortic Aneurysm Global Clinical Trials Review, H2, 2018
Abdominal Aortic Aneurysm Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial ...
25 Oct 2018 by Global Data USD $2,500 More Info
Abdominal Abscess Global Clinical Trials Review, H2, 2018
Abdominal Abscess Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, ...
25 Oct 2018 by Global Data USD $2,500 More Info
Interventional Cardiology & Peripheral Vascular Devices Market by Type (Angioplasty Balloon, Stent, Catheters, EVAR Stent Grafts, Abdominal Aortic Aneurysm, IVC Filter, Plaque Modification, Hemodynamic Flow Alteration, Accessories, Guidewire) - Forecasts to 2021
The interventional cardiology and peripheral vascular devices market is expected to reach USD 31.47 ...
16 Dec 2016 by MarketsandMarkets USD $5,650 More Info
Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016
Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical...
01 Oct 2016 by Global Data USD $4,000 More Info
Abdominal Pain Global Clinical Trials Review, H2, 2016
Abdominal Pain Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Ab...
17 Aug 2016 by Global Data USD $2,500 More Info
Abdominal Pain Global Clinical Trials Review, H2, 2016
Abdominal Pain Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Ab...
17 Aug 2016 by Global Data USD $2,500 More Info
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2016
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial...
20 Jan 2016 by Global Data USD $2,500 More Info
Closed MRI Systems Market, by Field Strength (Low-to-Mid Field, High Field, Very High Field, Ultra High Field) & by Application (Brain, Spine, Cardiac, Breast, Abdominal) -Global Forecast to 2019
The purpose of this report is to cover the definition, description, and forecast of the global MRI s...
02 May 2015 by MicroMarketMonitor USD $4,250 More Info

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Abdominal Obesity Metabolic Syndrome Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...